dBET1 is primarily used in biomedical research as a targeted protein degradation tool. It functions by recruiting specific proteins involved in cancer progression, particularly transcription factors like BRD4, to E3 ubiquitin ligases, leading to their ubiquitination and subsequent degradation by the proteasome. This mechanism makes dBET1 valuable in studying oncogenic signaling pathways in cancers such as acute myeloid leukemia (AML) and other hematologic malignancies. Researchers use dBET1 to probe the therapeutic potential of targeted protein degradation, especially in cases where traditional inhibition methods are ineffective. Its application supports the development of novel therapies based on molecular glues and PROTACs (proteolysis-targeting chimeras), offering a promising strategy for undruggable targets.